TSPO and central nervous system cancer: PLX5622 treatment successfully depleted most Iba1+ cells in glioma-bearing mice compared with the nontreated group (P ≤ 0.05), in both the ipsilateral and the contralateral hemispheres, in line with TSPO PET.